Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year—Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS)

Table 3

Inclusion and exclusion criteria of the HREVS trial.

Inclusion criteria

Exclusion criteria

1. Male or female ≥18 years of age; 2. II–IV Canadian Cardiovascular Society functional; class of angina; 3. Angiographically confirmed multivessel coronary; artery diseases involving LAD, with lesions severity; ≥70% diameter stenosis (DS) by quantitative; coronary angiography (QCA), or 50–70% DS with; functional evidence of ischemia by either FFR ≤0.80 or stress SPECT; 4. At least 1 month after acute MI (in patients with; history of MI); 5. Heart team-determined indication to coronary; revascularization with equal feasibility to perform complete revascularization using either of the three; methods (HCR, MVD-PCI, CABG); 6. Written informed consent for participation in the; study, including random treatment allocation and; compliance with study requirements inclusive of; follow-up visits and 12 ± 1 month SPECT followed by; control angiography

1. Acute coronary syndrome (ACS); 2. Any previous coronary revascularization (CABG,; HCR, or PCI); 3. Presence of any condition or abnormality that in; the opinion of the investigator would compromise; the safety of the patient or the quality of the data; 4. Pregnancy; 5. Stenosis of the left main coronary artery requiring; revascularization; 6. Significant calcification or occlusion of a major; coronary vessel; 7. Left ventricle aneurysm or valvular heart disease; requiring surgical management; 8. Comorbidity associated with an increased; procedural risk for any of the treatment strategies or; other study procedures; 9. Peripheral arterial disease with pain-free walking; distance ≤50m; 10. Life expectancy ≤5 years; 11. Inability to comply with dual antiplatelet therapy; (DAPT); 12. Inability to undergo follow-up procedures; including long-term follow-up; 13. Participation in another clinical study